Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06618014
PHASE2

Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)

Sponsor: Sun Yat-sen University

View on ClinicalTrials.gov

Summary

This study aims to investigate efficacy and safety of neoadjuvant toripalimab plus docetaxel and carboplatin in patients with localized triple-negative breast cancer.

Official title: A Single-Arm Phase II Trial of Neoadjuvant Toripalimab, Docetaxel, Plus Carboplatin in Patients With Localized Triple-Negative Breast Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - 69 Years

Study Type

INTERVENTIONAL

Enrollment

51

Start Date

2022-01-11

Completion Date

2027-12-31

Last Updated

2026-05-15

Healthy Volunteers

No

Interventions

DRUG

Toripalimab

Toripalimab was given 240 mg intravenously on day 1 of each 21-day cycle for 6 cycles.

DRUG

Docetaxel

Docetaxel was administered at a dose of 75 mg/m2 on day 1 of each 21-day cycle for 6 cycles.

DRUG

Carboplatin

Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 4 on day 1 of each 21-day cycle for 6 cycles.

Locations (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China